In:
Oncology, S. Karger AG, Vol. 87, No. 1 ( 2014), p. 7-20
Kurzfassung:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Mutations in the 〈 i 〉 KRAS 〈 /i 〉 gene have been identified as negative predictors of response to anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapy by patients with metastatic colorectal cancer (mCRC). However, it has been based on the study of mainly Caucasian mCRC patients. This prospective study investigated the relationship between the mutation status of EGFR-related genes including 〈 i 〉 KRAS 〈 /i 〉 and the response rate (RR) to cetuximab plus irinotecan therapy in Japanese mCRC patients. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Samples taken from 43 chemotherapy-refractory mCRC patients who had undergone cetuximab plus irinotecan therapy at 11 medical centers in Japan were subjected to direct DNA sequencing to determine the 〈 i 〉 KRAS, BRAF, PIK3CA, NRAS, 〈 /i 〉 and 〈 i 〉 AKT1 〈 /i 〉 mutation status. The clinical outcome after the treatment was evaluated for each mutation status. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 〈 i 〉 KRAS 〈 /i 〉 mutations were detected in 31.7% of 41 eligible patients. The RR to cetuximab plus irinotecan therapy was found to be 17.9 and 0% in the 〈 i 〉 KRAS 〈 /i 〉 wild-type and mutant subgroups, respectively. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 Despite the identification of a lower-than-expected RR to treatment by the 〈 i 〉 KRAS 〈 /i 〉 wild-type subgroup, 〈 i 〉 KRAS 〈 /i 〉 mutation status appears to be a useful predictive marker of response to cetuximab plus irinotecan therapy in Japanese mCRC patients.
Materialart:
Online-Ressource
ISSN:
0030-2414
,
1423-0232
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2014
ZDB Id:
1483096-6
ZDB Id:
250101-6
